Summit Therapeutics Inc
SMMT20.950USD
+0.690+3.41%
Handelsschluss 09/26, 16:00（ET）Kurse um 15 Minuten verzögert
15.56BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unternehmen
Unternehmensinformationen
BörsenkürzelSMMT
Name des UnternehmensSummit Therapeutics Inc
IPO-datumOct 14, 2004
CEODr. Mahkam (Maky) Zanganeh
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeOct 14
Addresse601 Brickell Key Drive
StadtMIAMI
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl33131
Telefon13052032034
Websitehttps://www.smmttx.com/
BörsenkürzelSMMT
IPO-datumOct 14, 2004
CEODr. Mahkam (Maky) Zanganeh
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
556.09M
+0.06%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
556.09M
+0.06%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Latin America
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 23
Aktualisiert: Sat, Aug 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Duggan (Robert William)
74.86%
Zanganeh (Mahkam)
4.81%
Baker Bros. Advisors LP
4.54%
Xia (Yu)
4.24%
Fidelity Management & Research Company LLC
1.24%
Andere
10.30%
Aktionäre
Aktionäre
Anteil
Duggan (Robert William)
74.86%
Zanganeh (Mahkam)
4.81%
Baker Bros. Advisors LP
4.54%
Xia (Yu)
4.24%
Fidelity Management & Research Company LLC
1.24%
Andere
10.30%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
84.35%
Investment Advisor
5.54%
Hedge Fund
5.14%
Investment Advisor/Hedge Fund
2.32%
Research Firm
0.25%
Sovereign Wealth Fund
0.19%
Pension Fund
0.07%
Bank and Trust
0.06%
Andere
2.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
447
727.40M
97.94%
-484.11K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Duggan (Robert William)
555.75M
74.83%
+74.55K
+0.01%
May 30, 2025
Zanganeh (Mahkam)
35.74M
4.81%
+359.73K
+1.02%
Apr 15, 2025
Baker Bros. Advisors LP
24.42M
3.29%
--
--
Mar 31, 2025
Xia (Yu)
31.52M
4.24%
--
--
Apr 15, 2025
Fidelity Management & Research Company LLC
9.31M
1.25%
+1.29M
+16.12%
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
1.57%
-30.07K
-0.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.51M
1.01%
-43.09K
-0.57%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
0.65%
-751.52K
-13.41%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.46M
0.87%
-11.97K
-0.19%
Mar 31, 2025
Soni (Manmeet Singh)
3.02M
0.41%
--
--
Apr 15, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Tema Oncology ETF
2.83%
ProShares Ultra Nasdaq Biotechnology
1.76%
Invesco Nasdaq Biotechnology ETF
1.76%
SPDR S&P Biotech ETF
1.07%
Invesco NASDAQ Next Gen 100 ETF
0.96%
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
Invesco ESG NASDAQ Next Gen 100 ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.61%
iShares Biotechnology ETF
0.25%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.21%
Mehr Anzeigen
Tema Oncology ETF
Anteil2.83%
ProShares Ultra Nasdaq Biotechnology
Anteil1.76%
Invesco Nasdaq Biotechnology ETF
Anteil1.76%
SPDR S&P Biotech ETF
Anteil1.07%
Invesco NASDAQ Next Gen 100 ETF
Anteil0.96%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.95%
Invesco ESG NASDAQ Next Gen 100 ETF
Anteil0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.61%
iShares Biotechnology ETF
Anteil0.25%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Anteil0.21%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
